|
Gene: CIC |
Gene summary for CIC |
Gene summary. |
Gene information | Species | Human | Gene symbol | CIC | Gene ID | 23152 |
Gene name | capicua transcriptional repressor | |
Gene Alias | MRD45 | |
Cytomap | 19q13.2 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | Q96RK0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23152 | CIC | LZE8T | Human | Esophagus | ESCC | 7.56e-05 | 4.99e-02 | 0.067 |
23152 | CIC | LZE24T | Human | Esophagus | ESCC | 6.72e-11 | 1.52e-01 | 0.0596 |
23152 | CIC | LZE6T | Human | Esophagus | ESCC | 2.69e-02 | 4.85e-02 | 0.0845 |
23152 | CIC | P1T-E | Human | Esophagus | ESCC | 2.45e-07 | 3.24e-01 | 0.0875 |
23152 | CIC | P2T-E | Human | Esophagus | ESCC | 4.14e-16 | 1.71e-01 | 0.1177 |
23152 | CIC | P4T-E | Human | Esophagus | ESCC | 1.61e-06 | 2.37e-02 | 0.1323 |
23152 | CIC | P5T-E | Human | Esophagus | ESCC | 4.79e-11 | -1.28e-02 | 0.1327 |
23152 | CIC | P8T-E | Human | Esophagus | ESCC | 2.06e-29 | 5.12e-01 | 0.0889 |
23152 | CIC | P9T-E | Human | Esophagus | ESCC | 4.31e-06 | -4.08e-03 | 0.1131 |
23152 | CIC | P10T-E | Human | Esophagus | ESCC | 2.53e-24 | 4.51e-01 | 0.116 |
23152 | CIC | P11T-E | Human | Esophagus | ESCC | 2.25e-03 | 1.41e-01 | 0.1426 |
23152 | CIC | P12T-E | Human | Esophagus | ESCC | 1.09e-10 | 7.74e-02 | 0.1122 |
23152 | CIC | P15T-E | Human | Esophagus | ESCC | 4.45e-08 | 1.50e-01 | 0.1149 |
23152 | CIC | P16T-E | Human | Esophagus | ESCC | 6.79e-06 | -4.64e-02 | 0.1153 |
23152 | CIC | P17T-E | Human | Esophagus | ESCC | 1.11e-11 | 2.04e-01 | 0.1278 |
23152 | CIC | P19T-E | Human | Esophagus | ESCC | 4.92e-03 | 1.75e-01 | 0.1662 |
23152 | CIC | P20T-E | Human | Esophagus | ESCC | 1.63e-12 | 5.05e-02 | 0.1124 |
23152 | CIC | P21T-E | Human | Esophagus | ESCC | 8.14e-11 | -8.30e-03 | 0.1617 |
23152 | CIC | P22T-E | Human | Esophagus | ESCC | 4.54e-18 | 5.02e-02 | 0.1236 |
23152 | CIC | P23T-E | Human | Esophagus | ESCC | 9.04e-17 | 1.10e-01 | 0.108 |
Page: 1 2 3 4 5 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501728 | Esophagus | ESCC | Spinocerebellar ataxia | 94/4205 | 143/8465 | 6.77e-05 | 2.90e-04 | 1.48e-04 | 94 |
hsa0501736 | Esophagus | ESCC | Spinocerebellar ataxia | 94/4205 | 143/8465 | 6.77e-05 | 2.90e-04 | 1.48e-04 | 94 |
hsa0501721 | Liver | HCC | Spinocerebellar ataxia | 92/4020 | 143/8465 | 3.20e-05 | 1.88e-04 | 1.04e-04 | 92 |
hsa0501731 | Liver | HCC | Spinocerebellar ataxia | 92/4020 | 143/8465 | 3.20e-05 | 1.88e-04 | 1.04e-04 | 92 |
hsa0501725 | Oral cavity | OSCC | Spinocerebellar ataxia | 86/3704 | 143/8465 | 5.21e-05 | 2.08e-04 | 1.06e-04 | 86 |
hsa05017111 | Oral cavity | OSCC | Spinocerebellar ataxia | 86/3704 | 143/8465 | 5.21e-05 | 2.08e-04 | 1.06e-04 | 86 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CIC | SNV | Missense_Mutation | c.133N>A | p.Ala45Thr | p.A45T | Q96RK0 | protein_coding | deleterious_low_confidence(0.05) | possibly_damaging(0.746) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
CIC | SNV | Missense_Mutation | novel | c.2444N>A | p.Ala815Asp | p.A815D | Q96RK0 | protein_coding | tolerated_low_confidence(0.39) | benign(0.029) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
CIC | SNV | Missense_Mutation | c.662N>A | p.Arg221His | p.R221H | Q96RK0 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-B5-A0K6-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CIC | SNV | Missense_Mutation | c.683N>A | p.Arg228Gln | p.R228Q | Q96RK0 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-B5-A11Y-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CIC | SNV | Missense_Mutation | c.1318C>T | p.Arg440Cys | p.R440C | Q96RK0 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.948) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CIC | SNV | Missense_Mutation | novel | c.4000C>T | p.Arg1334Trp | p.R1334W | Q96RK0 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CIC | SNV | Missense_Mutation | c.1715N>A | p.Arg572Gln | p.R572Q | Q96RK0 | protein_coding | deleterious_low_confidence(0.03) | benign(0.078) | TCGA-BG-A0VZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | CR | |
CIC | SNV | Missense_Mutation | rs778167932 | c.4249N>T | p.Arg1417Cys | p.R1417C | Q96RK0 | protein_coding | deleterious(0) | probably_damaging(0.94) | TCGA-BG-A0YV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CIC | SNV | Missense_Mutation | c.4004C>A | p.Pro1335His | p.P1335H | Q96RK0 | protein_coding | deleterious(0) | possibly_damaging(0.769) | TCGA-BS-A0TJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
CIC | SNV | Missense_Mutation | c.4682C>T | p.Ser1561Leu | p.S1561L | Q96RK0 | protein_coding | tolerated_low_confidence(0.29) | benign(0) | TCGA-BS-A0TJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
23152 | CIC | CLINICALLY ACTIONABLE, DRUG RESISTANCE | TRAMETINIB | TRAMETINIB | 28178529 | |
23152 | CIC | CLINICALLY ACTIONABLE, DRUG RESISTANCE | SELUMETINIB | SELUMETINIB | 28178529 | |
23152 | CIC | CLINICALLY ACTIONABLE, DRUG RESISTANCE | VEMURAFENIB | VEMURAFENIB | 28178529 |
Page: 1 |